Gillian Cannon Sells 1,190 Shares of Xenon Pharmaceuticals (NASDAQ:XENE) Stock

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Director Gillian Cannon sold 1,190 shares of the firm’s stock in a transaction dated Friday, June 5th. The shares were sold at an average price of $53.14, for a total value of $63,236.60. Following the completion of the transaction, the director owned 1,455 shares of the company’s stock, valued at $77,318.70. The trade was a 44.99% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Xenon Pharmaceuticals Price Performance

Shares of NASDAQ XENE opened at $52.79 on Wednesday. The stock has a market capitalization of $5.10 billion, a price-to-earnings ratio of -11.23 and a beta of 0.62. The business has a 50-day moving average of $55.71 and a 200-day moving average of $48.77. Xenon Pharmaceuticals Inc. has a fifty-two week low of $30.00 and a fifty-two week high of $63.95.

Xenon Pharmaceuticals (NASDAQ:XENE) last issued its earnings results on Thursday, May 7th. The biopharmaceutical company reported ($1.17) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($1.17). During the same quarter last year, the company earned ($0.83) earnings per share. On average, sell-side analysts expect that Xenon Pharmaceuticals Inc. will post -4.92 EPS for the current year.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on XENE. Wells Fargo & Company reiterated an “overweight” rating and issued a $69.00 target price on shares of Xenon Pharmaceuticals in a research note on Sunday, May 10th. Wolfe Research began coverage on shares of Xenon Pharmaceuticals in a research note on Monday, February 23rd. They issued an “outperform” rating and a $60.00 target price for the company. Royal Bank Of Canada raised their target price on shares of Xenon Pharmaceuticals from $80.00 to $82.00 and gave the company an “outperform” rating in a research note on Friday, May 8th. Robert W. Baird raised their target price on shares of Xenon Pharmaceuticals from $63.00 to $97.00 and gave the company an “outperform” rating in a research note on Monday, March 9th. Finally, HC Wainwright raised their target price on shares of Xenon Pharmaceuticals from $53.00 to $74.00 and gave the company a “buy” rating in a research note on Tuesday, March 10th. Two equities research analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the stock has an average rating of “Buy” and a consensus price target of $77.20.

Institutional Investors Weigh In On Xenon Pharmaceuticals

Several hedge funds have recently bought and sold shares of XENE. Danske Bank A S acquired a new stake in Xenon Pharmaceuticals during the third quarter worth approximately $32,000. Blue Trust Inc. lifted its position in Xenon Pharmaceuticals by 2,560.7% during the fourth quarter. Blue Trust Inc. now owns 745 shares of the biopharmaceutical company’s stock worth $33,000 after acquiring an additional 717 shares during the last quarter. Kestra Advisory Services LLC acquired a new stake in Xenon Pharmaceuticals during the fourth quarter worth approximately $33,000. Aster Capital Management DIFC Ltd acquired a new stake in Xenon Pharmaceuticals during the third quarter worth approximately $39,000. Finally, Osaic Holdings Inc. lifted its position in Xenon Pharmaceuticals by 541.4% during the second quarter. Osaic Holdings Inc. now owns 1,225 shares of the biopharmaceutical company’s stock worth $40,000 after acquiring an additional 1,034 shares during the last quarter. 95.45% of the stock is currently owned by institutional investors and hedge funds.

Xenon Pharmaceuticals Company Profile

Xenon Pharmaceuticals Inc is a clinical?stage biopharmaceutical company dedicated to discovering and developing novel, small?molecule drugs targeting ion channels in the central and peripheral nervous system. The company’s research focus centers on neurological and pain disorders—including epilepsy, migraine, and neuropathic pain—by modulating key ion?channel proteins to restore normal neuronal function. Xenon’s scientific platform draws upon advances in ion?channel biology and structure?based drug design to identify and optimize therapeutic candidates with the potential for improved safety and efficacy profiles compared with existing treatments.

The company’s pipeline comprises multiple preclinical and clinical programs.